Stifel Financial Corp lessened its position in Aemetis, Inc. (NASDAQ:AMTX - Free Report) by 66.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 138,791 shares of the specialty chemicals company's stock after selling 280,703 shares during the period. Stifel Financial Corp owned approximately 0.27% of Aemetis worth $373,000 at the end of the most recent reporting period.
Other large investors have also modified their holdings of the company. Tower Research Capital LLC TRC grew its position in Aemetis by 128.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 10,407 shares of the specialty chemicals company's stock valued at $28,000 after buying an additional 5,859 shares in the last quarter. Barclays PLC grew its position in Aemetis by 14.7% in the 4th quarter. Barclays PLC now owns 54,492 shares of the specialty chemicals company's stock valued at $146,000 after buying an additional 6,996 shares in the last quarter. Wells Fargo & Company MN grew its position in Aemetis by 20.0% in the 4th quarter. Wells Fargo & Company MN now owns 45,741 shares of the specialty chemicals company's stock valued at $123,000 after buying an additional 7,622 shares in the last quarter. Geode Capital Management LLC grew its position in Aemetis by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 934,993 shares of the specialty chemicals company's stock valued at $2,516,000 after buying an additional 10,700 shares in the last quarter. Finally, Clear Harbor Asset Management LLC bought a new position in Aemetis in the 4th quarter valued at about $44,000. Institutional investors and hedge funds own 27.02% of the company's stock.
Aemetis Stock Up 6.3%
Shares of AMTX stock opened at $1.51 on Wednesday. Aemetis, Inc. has a 12 month low of $1.22 and a 12 month high of $4.73. The business's 50 day moving average is $1.59 and its two-hundred day moving average is $2.37. The company has a market cap of $80.51 million, a PE ratio of -0.67 and a beta of 1.47.
Aemetis (NASDAQ:AMTX - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The specialty chemicals company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.08). The business had revenue of $42.89 million for the quarter, compared to analysts' expectations of $59.35 million. During the same quarter in the previous year, the business earned ($0.58) earnings per share. As a group, equities analysts expect that Aemetis, Inc. will post -2.07 EPS for the current fiscal year.
Analyst Ratings Changes
A number of brokerages recently issued reports on AMTX. HC Wainwright reiterated a "buy" rating and issued a $28.00 target price on shares of Aemetis in a research report on Friday, March 14th. StockNews.com upgraded shares of Aemetis to a "sell" rating in a research report on Wednesday, February 5th. UBS Group reduced their price objective on shares of Aemetis from $2.50 to $2.20 and set a "buy" rating for the company in a research report on Friday, May 9th. Finally, Ascendiant Capital Markets raised their price objective on shares of Aemetis from $18.00 to $19.00 and gave the company a "buy" rating in a research report on Monday, March 17th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, Aemetis presently has an average rating of "Hold" and a consensus price target of $13.18.
Check Out Our Latest Research Report on Aemetis
About Aemetis
(
Free Report)
Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.
Further Reading
Want to see what other hedge funds are holding AMTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aemetis, Inc. (NASDAQ:AMTX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Aemetis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aemetis wasn't on the list.
While Aemetis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
